TMCnet News

Research and Markets Offers Report: High Throughput Screening (HTS) Market by Technology, Applications & by End Users - Forecast to 2018 [Health & Beauty Close - Up]
[April 22, 2014]

Research and Markets Offers Report: High Throughput Screening (HTS) Market by Technology, Applications & by End Users - Forecast to 2018 [Health & Beauty Close - Up]


(Health & Beauty Close - Up Via Acquire Media NewsEdge) Research and Markets has announced the addition of the "High Throughput Screening (HTS) Market by Technology, Applications & by End Users - Forecast to 2018" report to its offerings.



In a release, Research and Markets noted that report highlights include: The global HTS market was valued at $13,736 million in 2013 and is expected to reach $19,627 million by 2018, at a CAGR of 7.4 percent In recent years, the high throughput screening (HTS) market has witnessed a large number of technological advancements, which has resulted in an increase in the rate of adoption of HTS in laboratories.. The HTS market is broadly classified into five segments, namely, technologies, products, applications, end users, and geography.

The technology market is sub-divided into ultra high throughput screening, cell-based assays, lab-on-a chip, label-free technology, and bioinformatics. The cell-based assays segment dominated the HTS market in 2013, followed by the lab-on-a-chip segment. The HTS products market is broadly categorized into instruments, consumables/ reagents, and software and services. The consumables/reagents segment dominated this market in 2013, with a market share of around 57 percent. The applications market is segmented into target identification, primary screening, toxicology, stem cell biology, and others. Target identification dominated the HTS applications market in 2013, followed by the primary screening market. The HTS market by end user is broadly categorized into pharmaceutical companies, biotechnology companies, academic and government institutes, contract research organizations (CROs), and others. The pharmaceuticals segment dominated the market in 2013, with a market share of around 48 percent.


The major factors driving the growth of the HTS market are technological innovations, open innovation models adopted by pharmaceutical companies, increasing drug discovery initiatives by academic institutions, and huge capital investments in HTS technology by organizations. Moreover, the presence of a large untapped market in emerging countries and growth in outsourcing of drug discovery services especially in China and India are the various factors that are expected to provide growth opportunities for players in this market. However, the capital intensive nature of HTS and difficulties in assay development for novel target classes are the factors curbing the growth of this market.

Company Profiles -Agilent Technologies, Inc.

-Aurora Biomed -Axxam Spa -Beckman Coulter, Inc. (A Subsidiary Of Danaher) -Bio-Rad Laboratories -Biofocus Dpi Ltd.

-Intellicyt Corp.

-Luminex Corp.

-Perkinelmer, Inc.

-Sigma Aldrich Corp.

-Tecan Group Ltd.

-Thermo Fisher Scientific, Inc.

Report Information: www.researchandmarkets.com/research/2bnvzr/high_throughput ((Comments on this story may be sent to [email protected])) (c) 2014 ProQuest Information and Learning Company; All Rights Reserved.

[ Back To TMCnet.com's Homepage ]